Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats

Vaccine

Volumn 33, Issue 41, 2015, Pages 5406-5414

  Widjojoatmodjo, Myra N ^a   Bogaert, Lies ^a   Meek, Bob ^a,d   Zahn, Roland ^a   Vellinga, Jort ^a   Custers, Jerome ^a   Serroyen, Jan ^b   Radošević, Katarina ^c,e   Schuitemaker, Hanneke ^a  

^a Janssen Research and Development   (Netherlands)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c CRUCELL HOLLAND BV   (Netherlands)

^d ST ANTONIUS HOSPITAL   (Netherlands)

^e SANOFI   (France)

Author keywords

Ad26; Ad35; Adenovirus vector; Respiratory syncytial virus; RSV fusion protein; Vaccine

Indexed keywords

ADENOVIRUS TYPE 26 RESPIRATORY SYNCYTIAL VIRUS VACCINE FUSION PROTEIN; ADENOVIRUS TYPE 35 RESPIRATORY SYNCYTIAL VIRUS VACCINE FUSION PROTEIN; ADENOVIRUS VECTOR; FORMALDEHYDE; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; COTTON RAT; FEMALE; HUMAN ADENOVIRUS 26; HUMAN ADENOVIRUS 35; HUMAN ADENOVIRUS C; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFLAMMATORY INFILTRATE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SEROTYPE; SINGLE DRUG DOSE; VIRUS LOAD; ADENOVIRIDAE; ADMINISTRATION AND DOSAGE; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; GENE VECTOR; GENETICS; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNITY; IMMUNOLOGY; MOUSE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SECONDARY IMMUNIZATION; SERODIAGNOSIS; SIGMODONTINAE;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; FEMALE; GENETIC VECTORS; HUMANS; IMMUNITY; IMMUNIZATION; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; RATS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; SIGMODONTINAE; VIRAL FUSION PROTEINS;

EID: 84941877388     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.08.056     Document Type: Article

References (38)

1. Shay D.K., Holman R.C., Newman R.D., Liu L.L., Stout J.W., Anderson L.J. Bronchiolitis-associated hospitalizations among US children: 1980-1996. JAMA 1999, 282(15):1440-1446.
2. Falsey A.R., Hennessey P.A., Formica M.A., Cox C., Walsh E.E. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005, 352(17):1749-1759.
3. Hall C.B., Weinberg G.A., Iwane M.K., Blumkin A.K., Edwards K.M., Staat M.A., et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009, 360(6):588-598.
4. Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375(9725):1545-1555.
5. Anderson L.J., Dormitzer P.R., Nokes D.J., Rappuoli R., Roca A., Graham B.S. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine 2013, 31(Suppl. 2):B209-B215.
6. Graham B.S. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 2011, 239(1):149-166.
7. Hurwitz J.L. Respiratory syncytial virus vaccine development. Expert Rev Vaccines 2011, 10(10):1415-1433.
8. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89(4):422-434.
9. Connors M., Giese N.A., Kulkarni A.B., Firestone C.Y., Morse H.C., Murphy B.R. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 1994, 68(8):5321-5325.
10. Murphy B.R., Walsh E.E. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 1988, 26(8):1595-1597.
11. Vellinga J., Smith J.P., Lipiec A., Majhen D., Lemckert A., van Ooij M., et al. Challenges in manufacturing adenoviral vectors for global vaccine product deployment. Hum Gene Ther 2014, 25(4):318-327.
12. Zahn R., Gillisen G., Roos A., Koning M., van der Helm E., Spek D., et al. Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species. PLoS ONE 2012, 7(12):e44115.
13. Maizel J.V., White D.O., Scharff M.D. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2: 7A, and 12. Virology 1968, 36(1):115-125.
14. Fallaux F.J., Kranenburg O., Cramer S.J., Houweling A., Van Ormondt H., Hoeben R.C., et al. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 1996, 7(2):215-222.
15. Graham F.L., Smiley J., Russell W.C., Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977, 36(1):59-74.
16. Radosevic K., Rodriguez A., Lemckert A.A., van der Meer M., Gillissen G., Warnar C., et al. The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clin Vaccine Immunol 2010, 17(11):1687-1694.
17. Prince G.A., Prieels J.P., Slaoui M., Porter D.D. Pulmonary lesions in primary respiratory syncytial virus infection: reinfection, and vaccine-enhanced disease in the cotton rat (Sigmodon hispidus). Lab Invest 1999, 79(11):1385-1392.
18. Prince G.A., Curtis S.J., Yim K.C., Porter D.D. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 2001, 82(Pt 12):2881-2888.
19. Prince G.A., Jenson A.B., Horswood R.L., Camargo E., Chanock R.M. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol 1978, 93(3):771-791.
20. Niewiesk S., Prince G. Diversifying animal models: the use of hispid cotton rats (Sigmodon hispidus) in infectious diseases. Lab Anim 2002, 36(4):357-372.
21. Kohlmann R., Schwannecke S., Tippler B., Ternette N., Temchura V.V., Tenbusch M., et al. Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus. J Virol 2009, 83(23):12601-12610.
22. Fu Y., He J., Zheng X., Wu Q., Zhang M., Wang X., et al. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice. Biochem Biophys Res Commun 2009, 381(4):528-532.
23. Kim E., Okada K., Beeler J.A., Crim R.L., Piedra P.A., Gilbert B.E., et al. Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model. J Virol 2014, 88(9):5100-5108.
24. Johnson T.R., Rangel D., Graham B.S., Brough D.E., Gall J.G. Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation. Mol Ther 2013, 22(1):196-205.
25. Gnagi S.H., Schraff S.A. Nasal obstruction in newborns. Pediatr Clin North Am 2013, 60(4):903-922.
26. Prince G.A., Mond J.J., Porter D.D., Yim K.C., Lan S.J., Klinman D.M. Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. J Virol 2003, 77(24):13156-13160.
27. Wu H., Pfarr D.S., Johnson S., Brewah Y.A., Woods R.M., Patel N.K., et al. Development of motavizumab: an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007, 368(3):652-665.
28. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998, 102(3 Pt 1), 531-537.
29. Openshaw P.J., Chiu C. Protective and dysregulated T cell immunity in RSV infection. Curr Opin Virol 2013, 3(4):468-474.
30. de Cassan S.C., Draper S.J. Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets. Expert Rev Vaccines 2013, 12(4):365-378.
31. Thorner A.R., Vogels R., Kaspers J., Weverling G.J., Holterman L., Lemckert A.A., et al. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J Clin Microbiol 2006, 44(10):3781-3783.
32. Catanzaro A.T., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006, 194(12):1638-1649.
33. Barouch D.H., Kik S.V., Weverling G.J., Dilan R., King S.L., Maxfield L.F., et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 2011, 29(32):5203-5209.
34. Creech C.B., Dekker C.L., Ho D., Phillips S., Mackey S., Murray-Krezan C., et al. Randomized: placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults. Hum Vaccin Immunother 2013, 9(12):2548-2557.
35. Barouch D.H., Liu J., Peter L., Abbink P., Iampietro M.J., Cheung A., et al. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis 2013, 207(2):248-256.
36. Ouedraogo A., Tiono A.B., Kargougou D., Yaro J.B., Ouedraogo E., Kabore Y. A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. PLoS One 2013, 8(11):e78679.
37. Baden L.R., Walsh S.R., Seaman M.S., Tucker R.P., Krause K.H., Patel A., et al. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis 2013, 207(2):240-247.
38. Liu J., Li H., Iampietro M.J., Barouch D.H. Accelerated heterologous adenovirus prime-boost SIV vaccine in neonatal rhesus monkeys. J Virol 2012, 86(15):7829-7835.